{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:46Z","timestamp":1792787926428,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Top-Priority Clinical Key Disciplines Construction Project","award":["NSFC(82270039)"],"award-info":[{"award-number":["NSFC(82270039)"]}]},{"name":"Shanghai Top-Priority Clinical Key Disciplines Construction Project","award":["NSFC(82270039)"],"award-info":[{"award-number":["NSFC(82270039)"]}]},{"name":"Shanghai Top-Priority Clinical Key Disciplines Construction Project","award":["NSFC(82270039)"],"award-info":[{"award-number":["NSFC(82270039)"]}]},{"name":"Shanghai Top-Priority Clinical Key Disciplines Construction Project","award":["NSFC(82270039)"],"award-info":[{"award-number":["NSFC(82270039)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13743-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:13:41Z","timestamp":1740039221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5073-3759","authenticated-orcid":false,"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"4","key":"13743_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"13743_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40.","journal-title":"Mol Cancer"},{"key":"13743_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"23","key":"13743_CR4","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1002\/cam4.3532","volume":"9","author":"Y Kanjanapan","year":"2020","unstructured":"Kanjanapan Y, Yip D. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy. Cancer Med. 2020;9(23):9027\u201335.","journal-title":"Cancer Med"},{"key":"13743_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2051-1426-2-19","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"13743_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M del Castillo","year":"2016","unstructured":"del Castillo M, Romero FA, Arg\u00fcello E, et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490\u20133.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"13743_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","volume":"77","author":"T Morelli","year":"2022","unstructured":"Morelli T, Fujita K, Redelman-Sidi G, et al. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022;77(3):304\u201311.","journal-title":"Thorax"},{"issue":"6","key":"13743_CR8","doi-asserted-by":"publisher","first-page":"ofab187","DOI":"10.1093\/ofid\/ofab187","volume":"8","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF, Pizzutilo P, Catino A, et al. Incidence of infections and predictors of mortality during checkpoint inhibitor immunotherapy in patients with advanced lung cancer: a retrospective cohort study. Open Forum Infect Dis. 2021;8(6):ofab187.","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"13743_CR9","doi-asserted-by":"publisher","first-page":"e13303","DOI":"10.1111\/sji.13303","volume":"98","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Diella L, Pizzutilo P, et al. Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: a monocentric retrospective cohort study. Scand J Immunol. 2023;98(3):e13303.","journal-title":"Scand J Immunol"},{"issue":"1","key":"13743_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cam4.4393","volume":"11","author":"JA Ross","year":"2022","unstructured":"Ross JA, Komoda K, Pal S, et al. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022;11(1):21\u20137.","journal-title":"Cancer Med"},{"key":"13743_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","volume":"141","author":"JD Karam","year":"2020","unstructured":"Karam JD, Noel N, Voisin AL, et al. Infectious complications in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020;141:137\u201342.","journal-title":"Eur J Cancer"},{"key":"13743_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","volume":"146","author":"K Fujita","year":"2019","unstructured":"Fujita K, Kim YH, Kanai O, et al. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy [J]. Respir Med. 2019;146:66\u201370.","journal-title":"Respir Med"},{"issue":"6","key":"13743_CR13","first-page":"457","volume":"44","author":"Oncology branch of the Chinese medical association, association C M","year":"2021","unstructured":"Oncology branch of the Chinese medical association, association C M. Chinese medical association guideline for clinical diagnosis and treatment of lung cancer. Chin Med J. 2021;44(6):457\u201390.","journal-title":"Chin Med J"},{"issue":"12","key":"13743_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B de Pauw","year":"2008","unstructured":"de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"13743_CR15","unstructured":"Qin S. Guidelines of Chinese society of clinical oncology(CSCO)management of immune checkpoint inhibitor-related toxicity. People's Medical Publishing House. 2019."},{"issue":"1","key":"13743_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(1):9\u201331.","journal-title":"Nat Rev Cancer."},{"issue":"17","key":"13743_CR17","doi-asserted-by":"publisher","first-page":"9394","DOI":"10.3390\/ijms22179394","volume":"22","author":"L Budisan","year":"2021","unstructured":"Budisan L, Zanoaga O, Braicu C, et al. Links between infections, lung cancer, and the immune system. Int J Mol Sci. 2021;22(17):9394.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"13743_CR18","first-page":"185","volume":"19","author":"SK Seo","year":"2005","unstructured":"Seo SK. Infectious complications of lung cancer. Oncology (Williston Park). 2005;19(2):185\u201394.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"13743_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/cancers15010081","volume":"15","author":"EA Burns","year":"2022","unstructured":"Burns EA, Gee K, Kieser RB, et al. Impact of infections in patients receiving pembrolizumab-based therapies for non-small cell lung cancer. Cancers (Basel). 2022;15(1):81.","journal-title":"Cancers (Basel)"},{"issue":"7109","key":"13743_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134.","journal-title":"Nature"},{"issue":"12","key":"13743_CR21","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","volume":"11","author":"T Reungwetwattana","year":"2016","unstructured":"Reungwetwattana T, Adjei AA. Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11(12):2048\u201350.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"13743_CR22","doi-asserted-by":"publisher","first-page":"10292","DOI":"10.3390\/ijms231810292","volume":"23","author":"A de Giglio","year":"2022","unstructured":"de Giglio A, Aprile M, di Federico A, et al. Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci. 2022;23(18):10292.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"13743_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"key":"13743_CR24","first-page":"5","volume":"1","author":"G Ahangari","year":"2018","unstructured":"Ahangari G. Effect of hyperlipidemia on cell mediated immunity; could it be as predisposing factor of cancer risk. Biomed J Sci Tech Res. 2018;1:5.","journal-title":"Biomed J Sci Tech Res"},{"issue":"5","key":"13743_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269\u201385.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"13743_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-016-0561-5","volume":"38","author":"G Caramori","year":"2016","unstructured":"Caramori G, Casolari P, Barczyk A, et al. COPD immunopathology. Semin Immunopathol. 2016;38(4):497\u2013515.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"13743_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","volume":"4","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers. 2018;4(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"13743_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nm.2731","volume":"18","author":"ST Holgate","year":"2012","unstructured":"Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18(5):673\u201383.","journal-title":"Nat Med"},{"issue":"10","key":"13743_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"13743_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Nat Cancer Center. 2024;4(1):47\u201353.","journal-title":"J Nat Cancer Center"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13743-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:13:47Z","timestamp":1740039227000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13743"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13743-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study achieved formal approval from the Clinical Research Unit (research approval number: KY2023572) and the Ethics Committee of Zhongshan Hospital (ethical number: B2024-009). This study was retrospective, and the Ethics Committee of Zhongshan Hospital waived the requirement of extra patient consent statements because written informed consent was obtained from all patients admitted to allow their medical records to be used in clinical observational studies. All identifying information was removed to protect patient confidentiality according to the requirement of the Ethics Committee of Zhongshan Hospital. This study was designed and conducted in accordance with the Declaration of Helsinki and local institutional standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}